News Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Staff September 11, 2023 Iframe sync Post navigation Previous: Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research ConferenceNext: Major shareholder announcement – BlackRock, Inc. More Stories Coronavirus COVID-19 Diagnostics Healthcare Mental Health News Patient Care Predictmedix AI Inc. Announces Proposed Name Change to QScreen AI Inc., Pioneering the Fusion of Quantum Computing and AI to Transform Healthcare Staff January 12, 2026 Coronavirus COVID-19 Diagnostics Healthcare Mental Health News Patient Care Predictmedix AI Inc. Announces Proposed Name Change to QScreen AI Inc., Pioneering the Fusion of Quantum Computing and AI to Transform Healthcare Staff January 12, 2026 Autism Brain Cancer Healthcare Medicaid Medicare Menopause Neurology News Pharmaceutical CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz’s Team and an “Evidence Sprint 2026” Focused on Grants, Research and Clinical Evidence Staff January 12, 2026
